Home › Bell Radar › ATTO

ATTOAttovia Therapeutics

US ExchangeHealth Care2026-08-05

Clinical-stage biopharma developing biparatopic biologics (ATTOBODY platform) for immune-mediated pruritic diseases.

$17IPO price

$289MRaised

$21.9Day-1 close

0.82%Day-1 return

Clinical-stage biopharma developing biparatopic biologics (ATTOBODY platform) for immune-mediated pruritic diseases.

Company description (source: StockAnalysis)

Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments. The company’s products include ATTO-1310, a novel ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31; developed for the treatment of chronic pruritic diseases such as CPUO, high-itch AD, cholestatic pruritus, and CKD-aP; ATTO-2306, an ATTOBODY-based, half-life-extended immunoglobuli...

医疗健康生物医药免疫学

51CFO read: CFO requires CMC cost modeling, rare-disease commercial readiness planning, and platform-technology valuation expertise.

Management details per the SEC prospectus.

Company profile SEC prospectus

Does your company need this kind of CFO?

51CFO is an investment banking team focused on the US market: US IPOs, reverse mergers, shell deals, SPAC and De-SPAC, SEC filings and post-listing follow-ons, run by one team from structure to opening bell. Free 30-minute listing-route diagnosis, answered within 24 hours.

Talk to us